McIlrath & Eck’s GSK GSK Stock Holding History

McIlrath & Eck’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-178	Closed	-$8K	–	804
2021 Q1	$8K	Hold	178	–	–	﹤0.01%	511
2020 Q4	$8K	Hold	178	–	–	﹤0.01%	459
2020 Q3	$8K	Hold	178	–	–	﹤0.01%	421
2020 Q2	$9K	Hold	178	–	–	﹤0.01%	374
2020 Q1	$8K	Buy	178 +28	+19%	+$1.49K	﹤0.01%	340
2019 Q4	$9K	Hold	150	–	–	﹤0.01%	384
2019 Q3	$8K	Sell	150 -160	-52%	-$8.23K	﹤0.01%	386
2019 Q2	$16K	Hold	310	–	–	0.01%	237
2019 Q1	$16K	Buy	310 +178	+135%	+$8.89K	0.01%	237
2018 Q4	$6K	Sell	132 -56	-30%	-$2.76K	﹤0.01%	337
2018 Q3	$9K	Sell	188 -20	-10%	-$1.02K	0.01%	299
2018 Q2	$10K	Hold	208	–	–	0.01%	275
2018 Q1	$10K	Hold	208	–	–	0.01%	257
2017 Q4	$9K	Buy	+208	New	+$9.61K	0.01%	293

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

McIlrath & Eck's GSK Position: Q2 2021 in Review

McIlrath & Eck sold out of GSK (GSK) in Q2 2021, closing a stake of 178 shares — an estimated $8K sold.

McIlrath & Eck first reported a position in GSK in Q4 2017 and held it in 14 quarters. The position peaked at $16K in Q2 2019. 798 funds tracked by Wall St. Rank hold GSK as of Q2 2021.

McIlrath & Eck reported no remaining GSK position as of Q2 2021 after selling out during the quarter.
McIlrath & Eck sold 178 GSK shares in Q2 2021, an estimated $8K.
McIlrath & Eck first reported a position in GSK in Q4 2017 and held it in 14 quarters.
McIlrath & Eck's GSK position peaked at $16K in Q2 2019.
798 funds tracked by Wall St. Rank held GSK as of Q2 2021.

Based on McIlrath & Eck's 13F filing for Q2 2021, filed 9 Aug 2021.